$ADVM

Adverum Biotechnologies Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$0.879 ▼-0.991%

Extented Hours

VOLUME

535,884

DAY RANGE

0.87 - 0.8999

52 WEEK

0.7954 - 3.86

Join Discuss about ADVM with like-minded investors

profile
@dros #droscrew
recently

Unusually active option classes on open October 4th $ADVM $TGP $VTNR $PROG $EA $MRK $BTU $XLE $OXY

141 Replies 15 👍 9 🔥

profile
@dros #droscrew
recently

Upgrades 7/23: $AAL $BANC $CBT $DHI $ERF $LIND $MMC $MNST $PLAN $SBUX $TPH $TTD $TX $UAL $VNE $VERI $WRLD $WSO  . Downgrades 7/23: $ADVM $DPZ $FTI $LPRO $MCRB $SAM $SQM

71 Replies 8 👍 10 🔥

profile
@thegiz18 #ivtrades
recently

$ADVM had a boo boo on drug trial, down over 50% after hours

82 Replies 8 👍 14 🔥

profile
@thegiz18 #ivtrades
recently

$ADVM another biotech with secondary offering

119 Replies 6 👍 11 🔥

Key Metrics

Market Cap

87.69 M

Beta

0.89

Avg. Volume

0.92 M

Shares Outstanding

98.77 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.

CEO: Leone Patterson

Website:

HQ: 800 Saginaw Drive Redwood City, 94063 California

Related News